

Original Research Article

## Cytotoxicity of curcumin against CD44<sup>±</sup> prostate cancer cells: Roles of miR-383 and miR-708

Reza Panahizadeh<sup>1,2</sup>, Mohammad Amin Vatankhah<sup>1,2</sup>, Farhad Jeddi<sup>3</sup>, AmirAhmad Arabzadeh<sup>4</sup>, Kazem Nejati-Koshki<sup>5</sup>, Ramin Salimnejad<sup>2</sup>, Nowruz Najafzadeh<sup>2,\*</sup>

<sup>1</sup>Students Research Committee, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

<sup>2</sup>Research laboratory for Embryology and Stem Cells, Department of Anatomical Sciences, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

<sup>3</sup>Department of Medical Genetics and Pathology, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

<sup>4</sup>Department of Surgery, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

<sup>5</sup>Pharmaceutical Sciences Research Center, Ardabil University of Medical Science, Ardabil, Iran

**Article history:**

Received: May 29, 2022

Received in revised form:

Nov 02, 2022

Accepted: Nov 02, 2022

Epub ahead of print

**\* Corresponding Author:**

Tel: +989104075700

Fax: +984533534703

nowruz30@gmail.com

**Keywords:**

Prostate neoplasms

MicroRNAs

hsa-miR-708-5p

hsa-miR-383-5p

Natural products

Curcumin

### Abstract

**Objective:** Cancer stem cells (CSCs) remaining in the tumor tissues after applying treatments may cause recurrence or metastasis of prostate cancer (PC). Curcumin has the promising potential to target CSCs. Here, we aim to evaluate the cytotoxic effects of curcumin on the expression of miR-383-5p and miR-708-5p and their target genes in CD44<sup>+</sup> CSCs and CD44<sup>-</sup> non-CSCs isolated from the PC3 prostate cancer cell line.

**Materials and Methods:** We used MTT assay to determine the optimal cytotoxic dose of curcumin on CD44<sup>±</sup> PC cells. Then, we assessed nuclear morphological changes using DAPI staining. We used Annexin V-FITC/PI to quantify apoptotic cell death. qRT-PCR was also used to detect miRNA and gene expression levels after curcumin treatment.

**Results:** Curcumin significantly enhanced the apoptosis in both CD44<sup>-</sup> and CD44<sup>+</sup> PC cells in a dose-dependent manner ( $p < 0.05$ ). The cytotoxicity of curcumin against CD44<sup>-</sup> cells ( $IC_{50}$  40.30±2.32  $\mu$ M) was found to be greater than that against CD44<sup>+</sup> cells ( $IC_{50}$  83.31±2.91  $\mu$ M). Also, curcumin promoted miR-383-5p and miR-708-5p overexpression while downregulating their target genes *LDHA*, *PRDX3*, and *RAP1B*, *LSD1*, respectively.

**Conclusion:** Our findings indicate that curcumin, by promoting the expression of tumor suppressors, miR-383-5p and miR-708-5p, and inhibiting their target genes, induced its cytotoxicity against CD44<sup>±</sup> PC cells. We trust that curcumin could be established as a promising adjuvant therapy to current PC treatment options following more research in clinical settings.

Please cite this paper as:

Panahizadeh R, Vatankhah M.A, Jeddi F, Arabzadeh A.A, Nejati-Koshki K, Salimnejad R, Najafzadeh N. Cytotoxicity of curcumin against CD44<sup>±</sup> prostate cancer cells: Roles of miR-383 and miR-708. Avicenna J Phytomed, 2023. Epub ahead of print.

## Introduction

According to GLOBOCAN 2020, prostate cancer (PC) incidence is almost 1.3 million per year. In 2020, PC accounted for 359,000 deaths worldwide (Sung et al., 2021). A more and deeper understanding of PC's pathogenesis and molecular basis is critical to improving treatments (Karayi and Markham, 2004; Moshtaghoun et al., 2021). It is estimated that genetic factors play a critical role in 40% of early-onset PCs and 5-10% of all PCs (Beebe-Dimmer et al., 2020). The prognosis of patients diagnosed with localized lesions of PC is good, but the survival rate of metastatic cases drops down to 31%. Radical surgery, radiation therapy, cryotherapy, and androgen deprivation therapy are commonly used to treat PC according to the stage of the tumors. Although applying appropriate treatments abolish the main part of the tumor, cancer stem cells (CSCs) remaining in the tumor tissues may cause recurrence or metastasis of the tumor (Harris and Kerr, 2017). CSCs, a small subset of tumor cells, have the ability for self-renewal and asymmetric division, making them less vulnerable to chemotherapy and radiotherapy. So, the reason behind the failure of chemotherapy is the inability of current chemotherapeutics to eliminate CSCs (DeSano and Xu, 2009). Several markers such as CD44, CD133, and ABCG2 have been introduced to identify prostate CSCs. CD44 is one of the main prostate CSC tumor markers, and its high expression has been associated with tumor proliferation, stemness gene expression, and metastatic colonization (Harris and Kerr, 2017).

microRNAs (miRNAs) are small non-coding RNAs that alter gene expression by post-transcriptional silencing of the genes (Mokabber et al., 2022). The first correlation between miRNAs and cancer was discovered over two decades ago. Since then, miRNAs have been investigated in almost all cancer types. Ingenious technological developments for

the detection of miRNAs in tissue and bodily fluids, the identification of the diagnostic and prognostic value of specific miRNAs, and the development of numerous miRNA delivery strategies for therapeutic intervention have all been made possible by this incredibly large amount of research (Nejati et al., 2021; Pahlavan et al., 2020; Sempere et al., 2021). miRNAs such as miR-708-5p and miR-383-5p have been shown to be remarkably downregulated in PC (Bucay et al., 2017; Saini et al., 2012). Recent studies have approved that CD44 is a direct target of miR-708 and miR-383. miR-708 is a negative regulator of CD44<sup>+</sup> prostate CSCs, which can be used for prognosis and diagnosis of PC. Induction of ectopic expression of miR-383 has inhibited the tumorigenesis process and metastasis in CD44<sup>+</sup> prostate CSCs. Downregulation of miR-708 and miR-383 has been correlated with poor prognosis, tumor growth, and recurrence in clinical specimens. Together, overexpressing miR-708 and miR-383 could serve as an excellent attempt to treat metastatic PC (Bucay et al., 2017; Saini et al., 2012).

Natural products are valuable resources that have been frequently used to discover and produce anti-cancer drugs (Bishayee and Sethi, 2016). Recent studies on plant extracts of tomato, soy, ginger, and garlic have shown that bioactive molecules derived from these extracts could diminish chemoresistance and tumor growth (Grainger et al., 2019; Liu et al., 2017a; Salehi et al., 2019; Samy et al., 2021). Curcumin or diferuloylmethane is a bioactive metabolite derived from the *Curcuma longa* L. plant, primarily used in Chinese traditional medicine. Curcumin is a phytochemical product whose anti-PC effects on the inhibition of proliferation, invasion, cellular adhesion, and angiogenesis of many tumors have been confirmed (Termini et al., 2020). Multiple studies have shown that curcumin and its analogs have promising potential to target CSCs (Li and Zhang, 2014; Ramasamy et

al., 2015). However, studies suggest that curcumin causes anti-cancer effects by regulating miRNAs and their downstream molecular pathways (Mirzaei et al., 2018; Zendejdel et al., 2019), the role of curcumin in the regulation of miR-708 and miR-383 expression has not been elucidated yet.

According to these facts, our objective is to assess the molecular mechanism of cytotoxicity of curcumin and the efficacy of curcumin on the regulation of miR-708-5p, miR-383-5p, and their target genes in prostate CSCs and non-CSCs.

## Materials and Methods

### Drugs and reagents

Curcumin (C1386) and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, M2128) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Curcumin was dissolved in dimethylsulfoxide (DMSO) and stored at -20°C.

### Cell culture

The human prostate cancer cell line, PC3, was obtained from the National Cell Bank of Iran (NCBI, Pasteur Institute, Tehran, Iran). Cells were grown in RPMI 1640 medium (Gibco, UK), containing 10 % fetal bovine serum (FBS, Gibco), penicillin, and streptomycin. Finally, the cells were incubated in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C.

### Isolation of CD44<sup>±</sup> cells by magnetic-activated cell sorting (MACS)

CD44- positive CSCs and CD44-negative non-CSCs were sorted using MACS. Concisely, PC3 prostate cancer cells were trypsinized and collected. Then, 10<sup>6</sup> cells were stained with anti-human CD44 primary antibody (Miltenyi Biotec, 130-095-180). After incubating the cell suspension with Anti-PE Micro Bead (Miltenyi Biotec, 130-048-801), the cells were passed through a MACS column within a magnetic field. CD44<sup>+</sup> cells

carrying the magnetic beads were retained inside the column and adsorbed onto the surface. We sorted the cells twice to achieve more than 95% pure cells.

### MTT assay

Concisely, the CD44<sup>±</sup> prostate cancer cells were seeded in 96-well plates. The CD44<sup>-</sup> cells were incubated in an RPMI1640 medium containing 0-70 μM curcumin. The CD44<sup>+</sup> prostate cancer cells were treated with 15-150 μM curcumin. Curcumin dosage was determined according to similar research and our previous studies (Mollazade et al., 2013; Nejati-Koshki et al., 2014; Vatankhah et al., 2022). After 48 hr of incubation, the medium was replaced with 180 ml FBS-free medium and 20 ml MTT (Sigma, M2128). Then the cells were incubated for 4 hr at 37°C. Then, 200 ml DMSO (Scharlau Chemie, and Barcelona, Spain) was used to dissolve formazan crystals. Finally, the absorbance was measured at 570 nm using an ELISA reader.

### Apoptosis assessment

The cytotoxicity and nuclear morphological changes induced by curcumin were examined by DAPI staining. Briefly, the CD44<sup>±</sup> cells (5 × 10<sup>4</sup> cells/well) were seeded into 6-well plates. The CD44<sup>-</sup> and CD44<sup>+</sup> cells were treated with 15-60 μM and 50-150 μM curcumin, respectively. Curcumin dosage was determined according to similar research and our previous studies (Mollazade et al., 2013; Nasiri et al., 2013; Nejati-Koshki et al., 2014; Vatankhah et al., 2022). Then, the cells were fixed and stained with DAPI (Fatehi-Agdam et al., 2021).

### Quantification of gene expression by real-time PCR

Total RNA was extracted from CD44<sup>±</sup> prostate cancer cells using TRIzol reagent (Invitrogen). The total RNA was reverse-transcribed into cDNA using a Viva 2-steps RT-PCR kit (Vivantis, USA). Briefly, we used SYBR Green PCR Master

Mix (EURx, Ltd, Poland) to perform qRT-PCR, and gene expression was analyzed using a Light Cycler 96 real-time PCR System (Roche Applied Science) (Fatehi-Agdam *et al.*, 2021; Khakbaz *et al.*, 2021). The PCR reaction was conducted in a total volume of 20  $\mu$ l containing 10  $\mu$ l of master mix, 4  $\mu$ l of cDNA, and 2  $\mu$ l of primer. Fold changes in gene expression were calculated using the  $\Delta\Delta$ Ct method relative to *GAPDH* gene expression. The primers are listed in Table 1.

### Quantitation of microRNAs by real-time PCR

The expression levels of miR-383-5p and miR-708-5p were measured using BON-miR miRNA cDNA Synthesis Kit (Cat: BON209001). The following primers were used in qPCR reactions: miR-383-5p (TAGATCAGAAGGTGATTG), miR-708-5p (GGAAGGAGCTTACAATCTA), and U6 (AAGGATGACACGCAA). Briefly, after polyadenylation, a PCR reaction was performed in a 10  $\mu$ l reaction containing 1.0  $\mu$ l reverse transcriptase (RT) enzyme, 10  $\mu$ M Bon-RT primer, 100 mM dNTP mix, and 2.0  $\mu$ l 10  $\times$  RT buffer. miRNA expression fold changes were evaluated using the comparative  $\Delta\Delta$ Ct method (Mokabber *et al.*, 2019).

### Flow cytometry

Human CD44<sup>+</sup> prostate cancer cells were cultivated at a density of  $5 \times 10^5$  cells/well in a 6-well plate. The CD44<sup>+</sup> cells were treated with subtoxic concentration of curcumin for 48 hr. The cells were counterstained with Annexin V-FITC (fluorescein isothiocyanate)/PI (propidium iodide) (IQ products, Netherlands) staining assay. Briefly,  $1 \times 10^6$  cells were centrifuged and rinsed with calcium-binding buffer, and 5  $\mu$ l of Annexin V/FITC was added to the cell suspension. Finally, analysis was performed by a flow cytometer (Partec CyFlow®) with emission filters of 515–545 nm for FITC (green) and 600 nm for PI (red) (Rahnamay *et al.*, 2018).

### Statistical analysis

Data analysis was performed using SPSS V.21 software. One-way ANOVA with Tukey's *post hoc* test was used for statistical comparisons. A p-value less than 0.05 was considered significant. The standard curves were drawn using sigma plot V.11 software (Systat Software, San Jose, CA).

## Results

### Curcumin induces cytotoxicity against CD44<sup>-</sup> cells and CD44<sup>+</sup> prostate cancer cells.

CD44<sup>+</sup> PC3 cells are shown in Figure 1. The cell survival rate was determined using the MTT cell proliferation assay. The IC<sub>50</sub> values of curcumin for CD44<sup>-</sup> and CD44<sup>+</sup> prostate cancer cells were  $40.30 \pm 2.32$   $\mu$ M and  $83.31 \pm 2.91$   $\mu$ M, respectively. The IC<sub>50</sub> value of curcumin against CD44<sup>-</sup> cells was significantly lower than that observed for CD44<sup>+</sup> cells ( $p < 0.05$ ).

Our results confirmed that curcumin inhibited both CD44<sup>-</sup> and CD44<sup>+</sup> prostate cancer cells in a dose-dependent manner. The cytotoxicity of curcumin against CD44<sup>-</sup> cells was more greater than that found for CD44<sup>+</sup> cells. Indeed, CD44<sup>+</sup> cells were more resistant to curcumin treatment (Figure 2).




Figure 1. Isolation of CD44<sup>+</sup> cells from PC3 cell line using MACS. CD44<sup>+</sup> cells were isolated and identified by fluorescence microscopy. The arrows show CD44<sup>+</sup> prostate CSCs.

## Cytotoxicity of curcumin against prostate cancer




Figure 2. Standard curve of the viability of CD44<sup>±</sup> PC3 cells treated with different concentrations of curcumin.

### The role of curcumin treatment on the morphology and apoptosis

Nuclear shrinkage, chromatin condensation, and pyknotic body formation were observed in response to the treatment with curcumin. Autophagic cell morphology was also seen after treatment with high doses of curcumin in CD44<sup>±</sup> PC3 cells (Figure 3 and Figure 4).

Indeed, flow cytometric results revealed that curcumin treatment increased

apoptotic cell rate compared to the control group in both CD44<sup>-</sup> and CD44<sup>+</sup> PC3 cells ( $p < 0.001$ ). curcumin 15 and 30 μM increased apoptotic rate in CD44<sup>-</sup> PC3 cells by  $30.15 \pm 4.03\%$  and  $39.72 \pm 1.61\%$ , respectively. In CD44<sup>+</sup> PC3 cells, 50 and 80 μM concentrations of curcumin significantly increased the apoptotic rate by  $34.57 \pm 1.30\%$  and  $43.86 \pm 1.52\%$ , respectively (Figure 5c and 5d,  $p < 0.05$ ).




Figure 3. DAPI staining of CD44<sup>-</sup> PC3 cells treated with 15 – 60 μM curcumin. Apoptotic cells are shown with arrows. Autophagic cells are marked with asterisks (a-g). \* $p < 0.05$  vs. control






Figure 4. DAPI staining of CD44<sup>+</sup> PC3 cells treated with 50 – 150 μM curcumin. Apoptotic bodies are shown with arrows and autophagic cells are marked with asterisks (a-g). \**p*<0.05 vs. control




Figure 5. Effects of curcumin on the apoptosis of CD44<sup>±</sup> PC3 cells. (A, C) Flow cytometric analysis and (B, D) apoptotic rates of CD44<sup>±</sup> PC3 cells treated with subtoxic concentrations of curcumin for 48 hr. Live cells: Q4, Apoptosis: Q2 and Q3, Necrotic cells: Q1. \**p* < 0.001 vs. control. PI, propidium iodide

### Curcumin promoted the expression of miR-383-5p and miR-708-5p while downregulating their target genes

To find possible target genes for miR-383-5p and miR-708-5p, we employed the bioinformatic algorithms miRbase and Target scan. We validated *LDHA* and *PRDX3* as probable targets of miR-383-5p

and *RAP1B* and *LSI1* as potential targets of miR-708-5p based on our *in-silico* study.

We found that curcumin significantly increases the expressions of miR-383-5p in both CD44<sup>+</sup> and CD44<sup>-</sup> prostate cancer cells (Figure 6a and 6d). We used real-time PCR to investigate whether curcumin

## Cytotoxicity of curcumin against prostate cancer

could silence target genes of miR-383-5p in the CD44<sup>+</sup> PC3 cells. Curcumin significantly suppressed *LDHA* and *PRDX3* (downstream targets of miR-383-5p) in CD44<sup>-</sup> cells (Figure 6b and 6c). Curcumin (80  $\mu$ M) significantly decreased the expression of *LDHA* and *PRDX3* in the CD44<sup>+</sup> cells, although 50  $\mu$ M curcumin had no discernible effect on their levels (Figure 6e and 6f).

We then detected the overexpression of miR-708-5p in the CD44<sup>+</sup> PC3 cells after

treatment with curcumin (Figure 7a and 7d). Curcumin (15 and 30  $\mu$ M) significantly decreased the expression of *RAP1B* and *LSD1* in CD44-negative cells ( $p < 0.05$ , Figure 7b and 7c). In CD44<sup>+</sup> cells, 80  $\mu$ M curcumin significantly inhibited the expression of *RAP1B* and *LSD1*. But only *LSD1* was suppressed by 50  $\mu$ M curcumin, and the change in *RAP1B* expression was statistically insignificant (Figure 7e and 7f).




Figure 6. Curcumin induced the expression of miR-383 while suppressing the expression of *LDHA* and *PRDX3* in CD44<sup>±</sup> PC3 cells. The CD44<sup>±</sup> PC3 cells were exposed to the subtoxic concentrations of curcumin according to  $IC_{50}$  values. qRT-PCR was used for the detection of miRNA and gene expression levels after curcumin treatment for 24 hr. All tests are performed three times. \* $p < 0.05$  and \*\* $p < 0.01$




Figure 7. Curcumin induced the expression of miR-708-5p while suppressing the expression of *RAP1B* and *LSD1* in CD44<sup>±</sup> PC3 cells. The cells were exposed to a subtoxic concentration of curcumin. qRT-PCR was used for the detection of miRNA and gene expression levels after curcumin treatment for 24 hr. All tests were performed three times. \* $p < 0.05$  and \*\* $p < 0.01$

## Discussion

Tumor resistance and recurrence often occur because the majority of conventional cancer therapies, such as chemotherapeutic agents and radiation, are unable to eradicate CSCs (Korkaya *et al.*, 2009; Shafee *et al.*, 2008). There are a variety of cytotoxic effects that curcumin exerts on CSCs. This is caused by a variety of features, including the inhibition of cytokine release, impacts at various points along the pathways for CSC self-renewal, and specific microRNAs that are dysregulated in CSCs (Li and Zhang, 2014; Sordillo and Helson, 2015).

Recent studies assessed the potential effect of curcumin on CSCs when used alone or in conjunction with other anticancer medications. Furthermore, multiple clinical trials have amply shown the safety and tolerability of curcumin (Li and Zhang, 2014). Here, we found that curcumin exerted its cytotoxic effects against both prostate CD44<sup>+</sup> CSCs and CD44<sup>-</sup> non-CSCs through induction of apoptosis in a dose-dependent manner. Also, our results revealed that CD44<sup>+</sup> cells were more resistant to curcumin than CD44<sup>-</sup> cells. Similar to our findings, Zhang *et al.* revealed that curcumin suppressed proliferative and invasive characteristics of human prostate CSCs through the induction of expression of specific miRNAs in the DLK1-DIO3 miRNA cluster (Zhang *et al.*, 2018a). Also, Liu *et al.* showed that curcumin treatment arrested the cell cycle and inhibited proliferation and metastasis in human prostate CSCs. They proposed that curcumin upregulates miR-145 and decreases proliferative characteristics of human prostate CSCs by inhibiting Oct4 expression (Liu *et al.*, 2017b).

Our results also showed that curcumin significantly increased nuclear shrinkage, chromatin condensation, and pycnotic body formation in both CD44<sup>-</sup> and CD44<sup>+</sup> PC3 cells in a dose-dependent manner. Consistent with our study, Zhang *et al.* observed apoptotic bodies and fragmented

nuclei in curcumin-treated human glioma CHME cells (Zhang *et al.*, 2018b). In another study, Kantara *et al.* showed that curcumin decreased the total number of tumorspheres and activated caspase-3 (Kantara *et al.*, 2014).

According to previous studies, curcumin inhibits the growth and invasion of human prostate CSCs *in vitro* by modifying certain miRNAs in the DLK1-DIO3 imprinted gene cluster, such as miR-770-5p and miR-1247 (Zhang *et al.*, 2018a). Additionally, curcumin (10 M) was capable of reducing the cell population with elevated levels of ALDH1, a hallmark specific for breast CSCs, from 7.3% to 1.5% (Ginestier *et al.*, 2007; Kakarala *et al.*, 2010). According to Zhuang *et al.*, curcumin caused glioma CSCs to differentiate and downregulated their capacity for self-renewal (Zhuang *et al.*, 2012). Additionally, while having various effects on CSCs, curcumin is not cytotoxic to normal stem cells (Sordillo and Helson, 2015).

In this study, we used curcumin as an attempt to induce the expression of tumor suppressor miRNAs, miR-708-5p and miR-383-5p in the human prostate CD44<sup>+</sup> CSCs and CD44<sup>-</sup> non-CSCs. Our results showed that curcumin significantly increased the expression level of miR-708-5p in both CD44<sup>+</sup> and CD44<sup>-</sup> cells in a dose-dependent manner. Similar to our study, many attempts have been made to induce the expression of miR-708 in different cancers. In 2012, miR-708 was first introduced as a therapeutic target of PC by Saini *et al.* They have revealed that induction of miR-708 expression in CD44<sup>+</sup> PC cells suppressed tumorigenicity. In contrast, the knockdown of miR-708 increased tumor growth in CD44<sup>-</sup> PC cells (Saini *et al.*, 2012). The therapeutic roles of miR-708 also have been confirmed in many cancers including prostate, breast, cervical and pancreatic carcinoma (Huang *et al.*, 2019; Ma *et al.*, 2016; Zou *et al.*, 2020). The low expression of miR-708 is involved in the neuroendocrine



differentiation of PC, which causes a poor prognosis in patients. In 2019, Shan et al. found that the overexpression of *EZH2* inhibits miR-708. They also found that induction of miR-708 reduces the number of CD44<sup>+</sup> neuroendocrine PC cells (Shan et al., 2019).

Also, our results showed that curcumin suppressed the expression of *RAP1B* and *LSD1*, two target genes of miR-708, which are also crucial in the pathogenesis of PC. Previous studies have shown that *LSD1* suppresses PC cell viability (Gao et al., 2020). Similar to our findings, Ma et al. demonstrated that suppression of *LSD1* might phenocopy the effect of miR-708 overexpression in MDA-MB-231 cells. Amplification of *LSD1* may offset miR-708's effects on invasion and proliferation. and the findings suggest that miR-708 may have a tumor suppressor gene role in the emergence of breast cancer (Ma et al., 2016). Furthermore, *RAP1B* expression is correlated with the immune infiltration of tumors in various cancers (Cui et al., 2021). In a similar study, Lin et al. showed that glucocorticoids reduce invasive characteristics of ovarian cancer by inducing the expression of miR-708 and inhibiting *RAP1B* (Lin et al., 2015).

Since CD44 is a hyaluronic acid receptor, it has a crucial role in the adhesion and migration of cancerous cells. At first, Bucay et al. showed that miR-383-5p, which is highly downregulated in PC, could be essential for PC metastasis and stemness by directly targeting CD44. The restoration of miR-383 expression in PC cells has proven anti-metastatic and anti-tumorigenic effects (Bucay et al., 2017).

Our results revealed that curcumin significantly increased the expression levels of miR-383-5p in both CD44<sup>+</sup> and CD44<sup>-</sup> cells. In a similar study, Lv et al. showed that allicin, a phytochemical extracted from garlic, induces miR-383 expression in gastric cancer. Allicin targets the miR-383/ERBB4 axis to inhibit the invasion of gastric cancer (Lv et al., 2020). A recent study conducted by Huang et al.

also approved that induction of miR-383 expression could inhibit growth and metastasis in PC (Huang et al., 2021). Conversely, downregulation of miR-383 by TMPO-AS1 in lung adenocarcinoma and pancreatic carcinoma and MIR4435-2HG in head and neck squamous cell carcinoma led to tumor progression (Mu et al., 2020; Wang et al., 2021; Xue et al., 2021).

Although tumor suppressive roles of miR-383 have been confirmed in various cancers such as malignant melanoma and glioma, it was shown that high miR-383 expression in cholangiocarcinoma is associated with advanced tumor stages, metastasis, and poor prognosis (Wan et al., 2018; Xu et al., 2021a; Xu et al., 2021b).

Our results also confirmed the downregulation of *PRDX3* and *LDHA*, target genes of miR-383, by curcumin in CD44<sup>±</sup> PC cells. *PRDX3* and *LDHA* are typically overexpressed in PC. *PRDX3*, acting as an antioxidant, protects PC cells from reactive oxygen species and promotes the survival of cancerous cells (Whitaker et al., 2013). *LDHA* plays a vital role in the Warburg effect (aerobic glycolysis) which provides a sufficient number of metabolites for the rapid growth of cancerous cells. Vieira et al. showed that overexpression of *LDHA* in the clinical specimen of PC patients is associated with therapeutic resistance (Vieira et al., 2021). In another study, the MYC-LDHA axis was shown to be important in PC pathogenesis, and FAM46B by targeting this axis, induces apoptosis and inhibits glycolysis in PC cells (Liang et al., 2020). Altogether, suppression of expression of *PRDX3* and *LDHA* is another aspect of the promising roles of curcumin in PC treatment.

Altogether, our study revealed that curcumin suppressed cellular proliferation and induced apoptosis in CD44<sup>+</sup> and CD44<sup>-</sup> PC cells. We also showed that curcumin, by promoting the expression of miR-383 and miR-708 and inhibiting their target genes, induced its cytotoxicity

against CD44<sup>±</sup> PC cells. Considering that traditional cancer chemotherapeutic agents and radiotherapy cannot eradicate CSCs, the cytotoxicity of curcumin against CD44<sup>+</sup> human prostate CSCs is a remarkable feature. We trust that curcumin could be established as a promising adjuvant to current PC treatment options following research in clinical settings.

### Acknowledgment

This study is a part of the MD thesis (IR.ARUMS.REC.1399.238) and is supported by Ardabil University of Medical Sciences. The authors would like to thank Dr. Elham Safarzadeh for kindly gifting the PC3 prostate cell line.

### Conflicts of interest

The authors declare that they have no conflict of interest

### References

- Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR, Cooney KA. 2020. Risk of prostate cancer associated with familial and hereditary cancer syndromes. *J Clin Oncol*, 38: 1807-1813.
- Bishayee A, Sethi G. 2016. Bioactive natural products in cancer prevention and therapy: Progress and promise. *Semin Caner Biol*, 40: 1-3.
- Bucay N, Sekhon K, Yang T, Majid S, Shahryari V, Hsieh C, Mitsui Y, Deng G, Tabatabai ZL, Yamamura S. 2017. MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. *Oncogene*, 36: 2667-2679.
- Cui G, Wang C, Lin Z, Feng X, Wei M, Miao Z, Sun Z, Wei F. 2021. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer. *Bioengineered*, 12: 4828-4840.
- DeSano JT, Xu L. 2009. MicroRNA regulation of cancer stem cells and therapeutic implications. *AAPS J*, 11: 682.
- Fatehi-Agdam M, Vatankhah MA, Panahizadeh R, Jeddi F, Najafzadeh N. 2021. Efficacy of metformin and chemotherapeutic agents on the inhibition of colony formation and Shh/Gli1 pathway: Metformin/docetaxel versus metformin/5-fluorouracil. *Drug Res*, 71: 17-25.
- Gao S, Chen S, Han D, Wang Z, Li M, Han W, Besschetnova A, Liu M, Zhou F, Barrett D. 2020. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. *Nat Genet*, 52: 1011-1017.
- Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell*, 1: 555-567.
- Grainger EM, Moran NE, Francis DM, Schwartz SJ, Wan L, Thomas-Ahner J, Kopec RE, Riedl KM, Young GS, Abaza R. 2019. A novel tomato-soy juice induces a dose-response increase in urinary and plasma phytochemical biomarkers in men with prostate cancer. *J Nutr*, 149: 26-35.
- Harris KS, Kerr BA. 2017. Prostate cancer stem cell markers drive progression, therapeutic resistance, and bone metastasis. *Stem Cells Int*, 2017: 8629234.
- Huang G, Guo X, Yang H. 2021. Long noncoding RNA SNHG1 promotes human prostate cancer progression by sponging miR-383-5p. *Anticancer Drugs*, 32: 286-295.
- Huang S, Guo H, Cao Y, Xiong J. 2019. MiR-708-5p inhibits the progression of pancreatic ductal adenocarcinoma by targeting Sirt3. *Pathol Res Pract*, 215: 794-800.
- Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G, Wicha MS. 2010. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. *Breast Cancer Res Treat*, 122: 777-785.
- Kantara C, O'Connell M, Sarkar S, Moya S, Ullrich R, Singh P. 2014. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA. Effects of DCLK1-siRNA±curcumin on cancer stem cells. *Can Res*, 74: 2487-2498.
- Karayi MK, Markham AF. 2004. Molecular biology of prostate cancer. *Prostate*

## Cytotoxicity of curcumin against prostate cancer

- Cancer Prostatic Dis, 7: 6-20.
- Khakbaz P, Panahizadeh R, Vatankhah MA, Najafzadeh N. 2021. Allicin reduces 5-fluorouracil-resistance in gastric cancer cells through modulating MDR1, DKK1, and WNT5A expression. *Drug Res*, 71: 448-454.
- Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS. 2009. Regulation of mammary stem/progenitor cells by PTEN/Akt/ $\beta$ -catenin signaling. *PLoS Biol*, 7: e1000121.
- Li Y, Zhang T. 2014. Targeting cancer stem cells by curcumin and clinical applications. *Cancer Lett*, 346: 197-205.
- Liang T, Ye X, Yan D, Deng C, Li Z, Tian B. 2020. FAM46B promotes apoptosis and inhibits glycolysis of prostate cancer through inhibition of the MYC-LDHA axis. *Onco Targets Ther*, 13: 8771-8782.
- Liu CM, Kao CL, Tseng YT., Lo YC, Chen CY. 2017a. Ginger phytochemicals inhibit cell growth and modulate drug resistance factors in docetaxel resistant prostate cancer cell. *Molecules*, 22: 1477.
- Liu T, Chi H, Chen J, Chen C, Huang Y, Xi H, Xue J, Si Y. 2017b. Curcumin suppresses proliferation and in vitro invasion of human prostate cancer stem cells by ceRNA effect of miR-145 and lncRNA-ROR. *Gene*, 631, 29-38.
- Lv Q, Xia Q, Li J, Wang Z. 2020. Allicin suppresses growth and metastasis of gastric carcinoma: The key role of microRNA-383-5p-mediated inhibition of ERBB4 signaling. *Biosci Biotechnol Biochem*, 84: 1997-2004.
- Ma L, Ma S, Zhao G, Yang L, Zhang P, Yi Q, Cheng S. 2016. miR-708/LSD 1 axis regulates the proliferation and invasion of breast cancer cells. *Can Med*, 5: 684-692.
- Mirzaei H, Masoudifar A, Sahebkar A, Zare N, Sadri Nahand J, Rashidi B, Mehrabian E, Mohammadi M, Mirzaei HR, Jaafari MR. 2018. MicroRNA: A novel target of curcumin in cancer therapy. *J Cell Physiol*, 233: 3004-3015.
- Mokabber H, Najafzadeh N, Mohammadzadeh Vardin M. 2019. miR-124 promotes neural differentiation in mouse bulge stem cells by repressing Ptbp1 and Sox9. *J Cell Physiol*, 234: 8941-8950.
- Mokabber H, Vatankhah MA, Najafzadeh, N. 2022. The regulatory role of microRNAs in the development, cyclic changes, and cell differentiation of the hair follicle. *Process Biochem*, 114: 36-41.
- Mollazade M, Nejati-Koshki K, Akbarzadeh A, Zarghami N, Nasiri M, Jahanban-Esfahlan R, Alibakhshi A. 2013. PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. *Asian Pac J Cancer Prev*, 14: 6925-6928.
- Moshtaghioun SM, Fazel-Yazdi N, Mandegari M, Shirinzadeh-Dastgiri A, Vakili M, Fazel-Yazdi H. 2021. Evaluation the presence of SERPINA5 (Exon 3) and FTO rs9939609 polymorphisms in papillary thyroid cancer patients. *Asian Pac J Cancer Prev*, 22: 3641-3646.
- Mu X, Wu H, Liu J, Hu X, Wu H, Chen L, Liu W, Luo S, Zhao Y. 2020. Long noncoding RNA TMPO-AS1 promotes lung adenocarcinoma progression and is negatively regulated by miR-383-5p. *Biomed Pharmacother*, 125: 109989.
- Nasiri M, Zarghami N, Koshki KN, Mollazadeh M, Moghaddam MP, Yamchi MR, Esfahlan RJ, Barkhordari A, Alibakhshi A. 2013. Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. *Asian Pac J Cancer Prev*, 14: 3449-3453.
- Nejati-Koshki K, Akbarzadeh A, Pourhassan-Moghaddam M. 2014. Curcumin inhibits leptin gene expression and secretion in breast cancer cells by estrogen receptors. *Can Cell Int*, 14: 66.
- Nejati K, Alivand M, Arabzadeh A. 2021. MicroRNA-22 in female malignancies: focusing on breast, cervical, and ovarian cancers. *Pathol Res Pract*, 223: 153452.
- Pahlavan Y, Nasr MM, Abdolahinia ED, Pirdel Z, Soofiyan SR, Siahpoush S, Nejati K. 2020. Prominent roles of microRNA-142 in cancer. *Pathol Res Pract*, 216: 153220.
- Rahnamay M, Mahdavi M, Shekarchi AA, Zare P, Feizi MAH. 2018. Cytotoxic and apoptosis inducing effect of some pyrano [3, 2-c] pyridine derivatives against MCF-7 breast cancer cells. *Acta Biochim Pol*, 65: 397-402.
- Ramasamy TS, Ayob AZ, Myint HHL, Thiagarajah S, Amini F. 2015. Targeting colorectal cancer stem cells using curcumin and curcumin analogues:

- insights into the mechanism of the therapeutic efficacy. *Can Cell Int*, 15: 96.
- Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, Zaman MS, Deng G, Tanaka Y, Dahiya R. 2012. miRNA-708 control of CD44+ prostate cancer-initiating cells. *Can Res*, 72: 3618-3630.
- Salehi B, Fokou PVT, Yamthe LRT, Tali BT, Adetunji CO, Rahavian A, Mudau FN, Martorell M, Setzer WN, Rodrigues CF. 2019. Phytochemicals in prostate cancer: from bioactive molecules to upcoming therapeutic agents. *Nutrients*, 11: 1483.
- Samy A, Shah D, Shahagadkar P, Shah H, Munirathinam G. 2021. Can diallyl trisulfide, a dietary garlic-derived compound, activate ferroptosis to overcome therapy resistance in prostate cancer? *Nutr Health*, 28: 207-212
- Sempere LF, Azmi AS, Moore A. 2021. microRNA-based diagnostic and therapeutic applications in cancer medicine. *Wiley Interdiscip Rev RNA*, 12: e1662.
- Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EYP. 2008. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. *Cancer Res*, 68: 3243-3250.
- Shan J, Al-Muftah MA, Al-Kowari MK, Abuaqel SW, Al-Rumaihi K, Al-Bozom I, Li P, Chouchane L. 2019. Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer. *Cell Death Discov*, 5: 1-13.
- Sordillo PP, Helson L. 2015. Curcumin and cancer stem cells: curcumin has asymmetrical effects on cancer and normal stem cells. *Anticancer Res*, 35: 599-614.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: Cancer J Clin*, 71: 209-249.
- Termini D, Den Hartogh DJ, Jaglanian A, Tsiani E. 2020. Curcumin against Prostate Cancer: Current Evidence. *Biomolecules*, 10: 1536.
- Vatankhah MA, Panahizadeh R, Nejati-Koshki K, Arabzadeh M, Arabzadeh AA, Najafzadeh N. 2022. Curcumin Upregulates miR-148a to Increase the Chemosensitivity of CD44-Positive Prostate Cancer Stem Cells to Paclitaxel Through Targeting the MSK1/IRS1 axis. *Drug Res*, 72: 457-465.
- Vieira FQ, Cardoso AR, Gigliano D, Carneiro I, Henrique R, Jerónimo C, Silva RA. 2021. LDHA and CPT2 association with therapy resistance in prostate cancer. *Eur J Public Health* 31.
- Wan P, Chi X, Du Q, Luo J, Cui X, Dong K, Bing Y, Heres C, Geller DA. 2018. miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1. *J Cell Biochem*, 119: 9720-9729.
- Wang S, Chen X, Qiao T. 2021. Long non-coding RNA MIR4435-2HG promotes the progression of head and neck squamous cell carcinoma by regulating the miR-383-5p/RBM3 axis. *Oncol Rep*, 45: 1-10.
- Whitaker H, Patel D, Howat W, Warren A, Kay J, Sangan T, Marioni J, Mitchell J, Aldridge S, Luxton H. 2013. Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. *Br J Can*, 109: 983-993.
- Xu H, Zhu X, Shi L, Lin N, Li X. 2021a. miR-383-5p inhibits human malignant melanoma cells function via targeting CENPF. *Reprod Biol*, 21: 100535.
- Xu Z, Zeng X, Li M, Liao, J, Chen Q. 2021b. MicroRNA-383 promotes reactive oxygen species-induced autophagy via downregulating peroxiredoxin 3 in human glioma U87 cells. *Exp Ther Med*, 21: 1-9.
- Xue F, Song X, Zhang S, Niu M, Cui Y, Wang Y, Zhao T. 2021. Long non-coding RNA TMPO-AS1 serves as a tumor promoter in pancreatic carcinoma by regulating miR-383-5p/SOX11. *Oncol Lett*, 21: 255.
- Zendehdel E, Abdollahi E, Momtazi-Borojeni AA, Korani M, Alavizadeh SH, Sahebkar A. 2019. The molecular mechanisms of curcumin's inhibitory effects on cancer stem cells. *J Cell Biochem*, 120: 4739-4747.
- Zhang H, Zheng J, Shen H, Huang Y, Liu T, Xi H, Chen C. 2018a. Curcumin suppresses in vitro proliferation and invasion of human prostate cancer stem cells by modulating DLK1-DIO3 imprinted gene cluster microRNAs. *Genet*

## Cytotoxicity of curcumin against prostate cancer

- Test Mol Biomark, 22: 43-50.
- Zhang Y, Tu L, Zhou X, Li B. 2018b. Curcumin-mediated induction of apoptosis in human glioma CHME cells. Med Sci Mon Basic Res, 24: 216.
- Zhuang W, Long L, Zheng B, Ji W, Yang N, Zhang Q, Liang Z. 2012. Curcumin promotes differentiation of glioma-initiating cells by inducing autophagy. Can Sci, 103: 684-690.
- Zou X, Zhu C, Zhang L, Zhang Y, Fu F, Chen Y, Zhou J. 2020. MicroRNA-708 suppresses cell proliferation and enhances chemosensitivity of cervical cancer cells to cDDP by negatively targeting timeless. OncoTargets Ther, 13: 225-235.